Department of Neurology, Xiangya Hospital, Central-South University, ChangSha, Hu Nan, China.
Acta Neurochir (Wien). 2011 Feb;153(2):319-25. doi: 10.1007/s00701-010-0750-2. Epub 2010 Aug 6.
Heme oxygenase-1 (HO-1), the rate-limiting enzyme for heme catabolism and iron production, its role in intracerebral hemorrhage (ICH) is controversial. The study was to investigate correlations between brain oxidative injury and HO-1 after experimental ICH.
Sprague-Dawley rats received intra-striatal infusions of 100 μl autologous whole blood as ICH models. HO-1 were examined by immunohistochemical and reverse transcription polymerase chain reaction (RT-PCR) analysis. Brain oxidative stress was quantitated by malondialdehyde (MDA); antioxidation were measured by copper-zinc superoxide dismutase (Cu/Zn-SOD) activity using RT-PCR assay.
The expression of the HO-1 upregulated and reached its peak at days 3 and 7 after ICH (P < 0.01). There was a significant increase of MDA and a top at 3-day post-ICH (P < 0.01); Cu/Zn-SOD was upregulated post-ICH and reached the top at day 7 (P < 0.001); HO-1 was correlated significantly with brain MDA content at days 7 and 14 following ICH (r = 0.435-0.501, P < 0.001) but there is no definite correlation between them on 1 to 3 days (P > 0.05); conversely, HO-1 was correlated significantly with Cu/Zn-SOD on 1 to 3 days after ICH (r = 0.433-0.621, P < 0.001) but there is no definite correlation between them at days 7 and 14 (P > 0.05).
HO-1 has both antioxidant and prooxidant properties in ICH. The early upregulation of HO-1 possibly fit with the events and be protective against oxidative stress, whereas its overexpression in the late stages may result in its dysfunction and be toxic. So it should be prudent to intervene ICH with the inhibitor/activator of HO-1.
血红素加氧酶-1(HO-1)是血红素分解和铁生成的限速酶,其在脑出血(ICH)中的作用存在争议。本研究旨在探讨实验性 ICH 后脑氧化损伤与 HO-1 的相关性。
Sprague-Dawley 大鼠接受自体全血 100 μl 纹状体内注射作为 ICH 模型。通过免疫组织化学和逆转录聚合酶链反应(RT-PCR)分析检测 HO-1。通过丙二醛(MDA)定量测定脑氧化应激;通过铜锌超氧化物歧化酶(Cu/Zn-SOD)活性的 RT-PCR 测定来衡量抗氧化作用。
HO-1 的表达上调,并在 ICH 后 3 天和 7 天达到峰值(P < 0.01)。MDA 显著增加,ICH 后 3 天达到峰值(P < 0.01);Cu/Zn-SOD 在 ICH 后上调,并在第 7 天达到峰值(P < 0.001);HO-1 与 ICH 后 7 天和 14 天的脑 MDA 含量呈显著相关(r = 0.435-0.501,P < 0.001),但在 1 天至 3 天之间无明确相关性(P > 0.05);相反,HO-1 与 ICH 后 1 天至 3 天的 Cu/Zn-SOD 呈显著相关(r = 0.433-0.621,P < 0.001),但在 7 天至 14 天之间无明确相关性(P > 0.05)。
HO-1 在 ICH 中具有抗氧化和促氧化特性。HO-1 的早期上调可能与氧化应激的发生和保护作用相吻合,而其在晚期的过度表达可能导致其功能障碍和毒性。因此,用 HO-1 的抑制剂/激活剂干预 ICH 应该谨慎。